If there is no overall survival benefit in metastatic breast cancer: Does it imply lack of efficacy? Taxanes as an example

Birgit E. P. J. Vriens, Dorien J. A. Lobbezoo, Joep P. J. de Hoon, Jurgen Veeck, Adri C. Voogd, Vivianne C. G. Tjan-Heijnen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)
Original languageEnglish
Pages (from-to)189-198
JournalCancer Treatment Reviews
Issue number2
Publication statusPublished - Apr 2013


  • Breast cancer
  • Chemotherapy
  • Taxanes
  • Docetaxel
  • Paclitaxel

Cite this